trending Market Intelligence /marketintelligence/en/news-insights/trending/jdx5USuxDSHF5BkvhqiXUg2 content esgSubNav
In This List

Neurotrope CEO resigns; replacement named

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Neurotrope CEO resigns; replacement named

Neurotrope Inc. appointed Charles Ryan as CEO and director after the resignation of Susanne Wilke.

Ryan's appointment as director is effective Dec. 18, and he will assume the role of CEO effective Feb. 15, 2018.

Currently, Ryan serves as the CEO and president of Orthobond Corp.

Neurotrope develops treatments for Alzheimer's and other neurodegenerative diseases.